Wanbury Enters Paediatric Dermatology Segment with Berrysoft Baby Range Launch
Wanbury Ltd · Press Release · 12 Oct 2026, 8:27 pm
Wanbury Enters Paediatric Dermatology Segment with Berrysoft Baby Range Launch Wanbury Skin Health Limited, a subsidiary of Wanbury Limited, launched its berrysoft™ baby skincare range across India on 12th Oct'26, marking its strategic entry into paediatric dermatology. The portfolio includes bathing bars, body wash, shampoo, and handwash, with lotions and diaper creams in the pipeline. The company secured GST registrations across five states and CFA drug licenses in four cities. Wanbury plans to cross-sell to paediatricians and engage dermatologists to expand its branded formulations presence across complementary healthcare categories.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement · 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates · 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. · 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. · 06 Nov 2026
- Financial Results as on 30th September, 2026 · 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 · 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. · 30 Oct 2026
